Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury

被引:312
作者
Lazarous, DF [1 ]
Shou, M [1 ]
Scheinowitz, M [1 ]
Hodge, E [1 ]
Thirumurti, V [1 ]
Kitsiou, AN [1 ]
Stiber, JA [1 ]
Lobo, AD [1 ]
Hunsberger, S [1 ]
Guetta, E [1 ]
Epstein, SE [1 ]
Unger, EF [1 ]
机构
[1] NHLBI,BIOSTAT RES BRANCH,NIH,BETHESDA,MD 20892
关键词
angiogenesis; collateral circulation muscle; smooth; growth substances;
D O I
10.1161/01.CIR.94.5.1074
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We have shown that the angiogenic peptides basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) enhance canine coronary collateral development when administered for greater than or equal to 4 weeks. bFGF, a pluripotent mitogen of mesodermally derived cells, could theoretically exacerbate neointimal smooth muscle cell hyperplasia, a fundamental component of atherosclerosis. VEGF, an endothelial cell-specific mitogen and vascular permeability factor, could have deleterious effects related to vascular hyperpermeability. The present investigation had two aims: (1) to ascertain whether brief (7-day) systemic arterial treatment with bFGF or VEGF would improve myocardial collateral perfusion and (2) to determine whether these peptides induce neointimal accumulation in vivo. Methods and Results Dogs were subjected to ameroid-induced occlusion of the left circumflex coronary artery and randomized to bFGF 1.74 mg (n=9), VEGF 0.72 mg (n=9), or saline (n=10) as a daily left atrial bolus (days 10 to 16). Additional dogs were randomized to VEGF 0.72 mg (n=6) or saline (n=5); however, treatment was delayed by 1 week. Coincident with the institution of treatment, all dogs underwent balloon denudation injury of the iliofemoral artery. bFGF markedly increased max collateral flow but did not exacerbate neointimal accumulation. VEGF had no discernible effect on maximal collateral flow, but it exacerbated neointimal thickening after vascular injury. Conclusions Short-term treatment with bFGF enhanced collateral development without increasing neointimal accumulation at sites of vascular injury. Although VEGF did not increase collateral development as administered in this study, it significantly exacerbated neointimal accumulation. These data provide support for the clinical investigation of bFGF in selected patients with ischemic heart disease.
引用
收藏
页码:1074 / 1082
页数:9
相关论文
共 40 条
[1]   LOCAL-DELIVERY OF VASCULAR ENDOTHELIAL GROWTH-FACTOR ACCELERATES REENDOTHELIALIZATION AND ATTENUATES INTIMAL HYPERPLASIA IN BALLOON-INJURED RAT CAROTID-ARTERY [J].
ASAHARA, T ;
BAUTERS, C ;
PASTORE, C ;
KEARNEY, M ;
ROSSOW, S ;
BUNTING, S ;
FERRARA, N ;
SYMES, JF ;
ISNER, JM .
CIRCULATION, 1995, 91 (11) :2793-2801
[2]   INTIMAL PROLIFERATION OF SMOOTH-MUSCLE CELLS AS AN EXPLANATION FOR RECURRENT CORONARY-ARTERY STENOSIS AFTER PERCUTANEOUS TRANS-LUMINAL CORONARY ANGIOPLASTY [J].
AUSTIN, GE ;
RATLIFF, NB ;
HOLLMAN, J ;
TABEI, S ;
PHILLIPS, DF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 6 (02) :369-375
[3]   INCREASED NUMBER OF MYOCARDIAL BLOOD-FLOW MEASUREMENTS WITH RADIONUCLIDE-LABELED MICROSPHERES [J].
BAER, RW ;
PAYNE, BD ;
VERRIER, ED ;
VLAHAKES, GJ ;
MOLODOWITCH, D ;
UHLIG, PN ;
HOFFMAN, JIE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1984, 246 (03) :H418-H434
[4]   ANGIOGENIC-INDUCED ENHANCEMENT OF COLLATERAL BLOOD-FLOW TO ISCHEMIC MYOCARDIUM BY VASCULAR ENDOTHELIAL GROWTH-FACTOR IN DOGS [J].
BANAI, S ;
JAKLITSCH, MT ;
SHOU, M ;
LAZAROUS, DF ;
SCHEINOWITZ, M ;
BIRO, S ;
EPSTEIN, SE ;
UNGER, EF .
CIRCULATION, 1994, 89 (05) :2183-2189
[5]   EFFECTS OF ACIDIC FIBROBLAST GROWTH-FACTOR ON NORMAL AND ISCHEMIC MYOCARDIUM [J].
BANAI, S ;
JAKLITSCH, MT ;
CASSCELLS, W ;
SHOU, M ;
SHRIVASTAV, S ;
CORREA, R ;
EPSTEIN, SE ;
UNGER, EF .
CIRCULATION RESEARCH, 1991, 69 (01) :76-85
[6]   RABBIT EAR MODEL OF INJURY-INDUCED ARTERIAL SMOOTH-MUSCLE CELL-PROLIFERATION - KINETICS, REPRODUCIBILITY, AND IMPLICATIONS [J].
BANAI, S ;
SHOU, M ;
CORREA, R ;
JAKLITSCH, MT ;
DOUEK, PC ;
BONNER, RF ;
EPSTEIN, SE ;
UNGER, EF .
CIRCULATION RESEARCH, 1991, 69 (03) :748-756
[7]   SITE-SPECIFIC THERAPEUTIC ANGIOGENESIS AFTER SYSTEMIC ADMINISTRATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
BAUTERS, C ;
ASAHARA, T ;
ZHENG, LP ;
TAKESHITA, S ;
BUNTING, S ;
FERRARA, N ;
SYMES, JF ;
ISNER, JM .
JOURNAL OF VASCULAR SURGERY, 1995, 21 (02) :314-325
[8]  
BRETSCHNEIDER HJ, 1963, ARZNEIMITTEL-FORSCH, V13, P255
[9]   VASCULAR-PERMEABILITY FACTOR - A TUMOR-DERIVED POLYPEPTIDE THAT INDUCES ENDOTHELIAL-CELL AND MONOCYTE PROCOAGULANT ACTIVITY, AND PROMOTES MONOCYTE MIGRATION [J].
CLAUSS, M ;
GERLACH, M ;
GERLACH, H ;
BRETT, J ;
WANG, F ;
FAMILLETTI, PC ;
PAN, YCE ;
OLANDER, JV ;
CONNOLLY, DT ;
STERN, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) :1535-1545
[10]  
COHEN MV, 1985, CORONARY COLLATERALS, P419